Recall events
/
Event 94066
Event summary
Timeline bucket February 20, 2024
Product types Drug
Classifications Class III
Statuses Ongoing
Recalling firm wording Contract Pharmaceuticals Limited Canada
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
2 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 2
Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61
D-0364-2024
Recall number D-0364-2024
Initiated February 20, 2024
Classification Class III
Status Ongoing
Quantity 45,875 bottles
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Out of specification
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.
Code information Lot #: 119466, 119467 Exp 04/2025; 120351 Exp 08/2025; 121712 Exp 11/2025
Distribution pattern Nationwide in the U.S. and Puerto Rico
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[13565]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 2
Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, L5N 6R8, NDC 71428-0003-60
D-0365-2024
Recall number D-0365-2024
Initiated February 20, 2024
Classification Class III
Status Ongoing
Quantity 11,750 bottles
App-derived interpretation
Potency or specification failure
reason.potency_specification_failure · v1.0.0
Out of specification
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.
Code information Lot #: 119874; Exp 06/30/2025
Distribution pattern Nationwide in the U.S. and Puerto Rico
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[13234]
FDA event record
· Exact recall-number query on openFDA